Omnicell (NASDAQ:OMCL) Releases Q4 2024 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its fourth quarter 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.550-0.620 for the period, compared to the consensus EPS estimate of 0.470. The company issued revenue guidance of $295.0 million-$305.0 million, compared to the consensus revenue estimate of $287.9 million. Omnicell also updated its FY 2024 guidance to 1.650-1.720 EPS.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on OMCL shares. Benchmark restated a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research note on Saturday, October 19th. JPMorgan Chase & Co. boosted their price objective on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research report on Friday, August 23rd. Craig Hallum increased their price objective on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Wells Fargo & Company lifted their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $49.14.

Omnicell Stock Performance

Shares of Omnicell stock traded up $0.03 on Friday, hitting $48.67. 683,792 shares of the company’s stock traded hands, compared to its average volume of 528,146. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 1.05. Omnicell has a one year low of $25.12 and a one year high of $55.74. The firm’s 50-day moving average price is $43.26 and its two-hundred day moving average price is $35.17.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. The firm had revenue of $276.80 million for the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. The company’s revenue was down 7.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.29 earnings per share. Equities analysts anticipate that Omnicell will post 0.64 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.